Tumor suppressor heterozygosity and homologous recombination deficiency mediate resistance to front-line therapy in breast cancer
Anton Mikhailovich Safonov, Antonio Marra, Chaitanya Bandlamudi, Ben O’Leary, Bradley Stephen Wubbenhorst, Emanuela Ferraro, Enrico Moiso, Minna Lee, Julia Ah-Reum An, Mark T.A. Donoghue, Marie Will, Fresia G. Pareja, Emily A. Nizialek, Natalia Lukashchuk, Eleni Sofianopoulou, , Pedram Razavi
The paper identifies how germline and somatic mutations interact to cause resistance to CDK4/6 inhibitors in breast cancer and proposes a sequential treatment strategy using PARP inhibitors.
bioRxiv · Feb 5, 2024 · PreprintGenomics